U.S. markets closed

Autolus Therapeutics plc (AUTL)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
6.44-0.10 (-1.53%)
At close: 4:00PM EST

Autolus Therapeutics plc

Forest House
58 Wood Lane White City
London W12 7RZ
United Kingdom
44 20 3829 6230

Full Time Employees290

Key Executives

NameTitlePayExercisedYear Born
Dr. Christian Martin ItinChairman & CEON/AN/A1964
Dr. Martin PuléFounder, Sr. VP, Chief Scientific Officer & DirectorN/AN/A1972
Mr. Andrew J. OakleyCFO & Sr. VPN/AN/A1962
Mr. Christopher VannSr. VP & COON/AN/A1965
Mr. David BrochuChief Technical OfficerN/AN/A1958
Mr. Matthias AlderSr. VP, Chief Bus. Officer, Gen. Counsel & Sec.N/AN/A1965
Dr. Muhammad Al-Hajj Ph.D.Sr. VP of Translational SciencesN/AN/A1971
Dr. Lucinda Crabtree Ph.D.VP of IR & Corp. CommunicationsN/AN/AN/A
Mr. Vishal MehtaVP & Head of Clinical OperationsN/AN/AN/A
Dr. Nushmia KhokharSr. VP of Clinical Devel.N/AN/AN/A
Amounts are as of and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of hematological malignancies and solid tumors. The company is developing AUTO1 and AUTO3 for B cell malignancies; AUTO2 for the treatment of multiple myeloma; AUTO4 and AUTO 5 for T cell lymphoma; and AUTO6 and AUTO7 to treat solid tumors. The company was founded in 2014 and is headquartered in London, the United Kingdom.

Corporate Governance

Autolus Therapeutics plc’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.